Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Commercial
  • Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’
  • Commercial

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

BioSpace

Analysts will be watching as a generic version of semaglutide--marketed by Novo Nordisk as Wegovy for weight loss--launches in Canada as a test case for future price erosion in the U.S.

Metabolic & GLP-1

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

BioSpace

Analysts will be watching as a generic version of semaglutide–marketed by Novo Nordisk as Wegovy for weight loss–launches in Canada as a test case for future price erosion in the U.S.

Metabolic & GLP-1

Read full story

Post navigation

Previous: Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact
Next: AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

Related Stories

  • Commercial

Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1

pharminent August 5, 2026
  • Commercial

Leqembi sales grow again after subcutaneous approvals

pharminent July 29, 2026
  • Commercial

Wegovy pill launches in UK as first daily oral GLP1 for weight management

pharminent July 6, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.